Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477922 | 0.85 | CYP2A6 (0.50) | CYP2A6CYP1A2RAB9AKDM4ECA12 | |
| SCHEMBL5541853 | 0.80 | CA12 (0.45) | CYP1A2RAB9AKDM4ECA12CA1 | |
| SCHEMBL5545251 | 0.77 | GPR3 (0.40) | CYP1A2RAB9AHSD17B10NPC1MEN1 | |
| SCHEMBL29447161 | 0.71 | CYP1A2 (0.79) | CYP2A6CYP1A2RAB9AKDM4ECA12 | |
| SCHEMBL443070 | 0.71 | CYP1A2 (0.79) | CYP2A6CYP1A2RAB9AKDM4ECA12 | |
| SCHEMBL5543787 | 0.69 | CYP2A6 (0.43) | CYP2A6CYP1A2KDM4EALDH1A1CYP11B2 | |
| SCHEMBL4462774 | 0.69 | CYP1A2 (0.43) | CYP2A6CYP1A2 | |
| SCHEMBL4459896 | 0.69 | CYP2A6 (0.43) | CYP2A6RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL16289083 | 0.69 | CYP1A2 (0.43) | CYP1A2KDM4ECA12CA1CA9 | |
| SCHEMBL645480 | 0.69 | CYP1A2 (0.55) | CYP2A6CYP1A2RAB9AKDM4ECA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2952096-B1 | Amide compound, an arthropod pest control agent and a method for controlling arthropod pest | SUMITOMO CHEMICAL CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9814235-B2 | Method for controlling arthropod pest | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-14 | — | — | US | disclosed |
| EP-2952096-A1 | METHOD FOR CONTROLLING ARTHROPOD PEST | Sumitomo Chemical Company, Limited (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20150344466-A1 | METHOD FOR CONTROLLING ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-12-03 | — | — | US | disclosed |
| US-20150005348-A1 | AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-01 | — | — | US | disclosed |
| EP-2813492-A1 | AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL | Sumitomo Chemical Co., Ltd (JP) | 2014-12-17 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7521454-B2 | Adenine derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1386923-B1 | NOVEL ADENINE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| CN-1250548-C | Novel adenine derivatives | SUMITOMO PHARMA (JP) | 2006-04-12 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1512992-A | Novel adenine derivatives | ס����ҩ��ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-4997836-A | Inhibitor of platelet activating factor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-03-05 | — | — | US | disclosed |
| US-4937246-A | ABSORBED EASILY FROM INTESTINES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-06-26 | — | — | US | disclosed |
| EP-0369810-A2 | PAF antagonists as anti-hyperendothelinemia agents | Takeda Chemical Industries, Ltd. (JP) | 1990-05-23 | — | — | EP | disclosed |
| EP-0368670-A1 | Trisubstituted piperazine compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-05-16 | — | — | EP | disclosed |
| EP-0318235-A2 | PAF antagonist, 1,4-disubstituted piperazine compounds and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344466-A1 | METHOD FOR CONTROLLING ARTHROPOD PEST | H1-0, H1-3, H1-2 | CYP2A6 961/4885CYP1A2 193/4885RAB9A 400/4885 |
| US-20150005348-A1 | AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL | RPS8, MT-CO2, ARG1 | CYP2A6 812/4885CYP1A2 355/4885RAB9A 375/4885 |
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | CYP2A6 3427/4885CYP1A2 628/4885RAB9A 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.